Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,347.60
(
-1.57%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
108.44
(
3.84%
)
Bitcoin
70,082.99
(
0.26%
)
News Focus
News Focus
Post# of 257264
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: masterlongevity post# 103967

Thursday, 09/16/2010 5:39:06 AM

Thursday, September 16, 2010 5:39:06 AM

Post# of 257264
GSK/GenMab advance Ofatumumab MS program to phase-2b using subcutaneous formulation, pending feedback from regulatory authorities:

http://finance.yahoo.com/news/GlaxoSmithKline-and-Genmab-pz-2645108315.html?x=0&.v=1

No further development of Ofatumuab will be undertaken in any indication using the IV formulation. Also, the Ofatumuab program in RA is “under review” by GSK/Genmab, which sounds like it’s going to be canned.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today